Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,480.00
(
-1.02%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
2.39%
)
Bitcoin
70,678.01
(
1.12%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 179844

Wednesday, 09/24/2014 12:02:20 PM

Wednesday, September 24, 2014 12:02:20 PM

Post# of 257264
GILD submits Japan NDA for Sovaldi + Ledipasvir combination in GT1 patients:

http://finance.yahoo.com/news/gilead-submits-drug-application-japan-040000790.html

Unlike the US and EU submissions for Sovaldi + Ledipasvir, the proposed duration of treatment is 12 weeks for all subgroups.

GILD submitted a Japan NDA for Sovaldi + ribavirin in GT2 patients in Jun 2014 (#msg-103797270). GT1b and GT2 comprise the overwhelming majority of HCV patients in Japan.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today